Andrew Gottesdiener
Independent DirectorDr. Andrew Gottesdiener, M.D., is Independent Director of Korsana Biosciences, Inc. Dr. Gottesdiener was Director of Lycia Therapeutics, Inc. from May 08, 2024 until July 2025. He served as Independent Director at Apogee Therapeutics, Inc. since June 2023 until May 11, 2026 and as a member of the board of managers of Apogee Therapeutics, LLC since 2022. Dr. Gottesdiener is a partner at Venrock Healthcare Capital Partners, an investment firm, in its New York office, where he focuses on healthcare investments. He serves as an Investment Professional at Venrock Management, LLC. He focuses on Biotechnology, Pharmaceuticals and healthcare investments at the firm. He is a part of Public Healthcare Team. He worked in the Appel Alzheimer’s Disease Research Institute at Weill Cornell where he was developing preclinical gene therapy platforms to treat Alzheimer’s disease. He earned his MD at Weill Cornell Medical College (2013-2018) during which he received an HHMI summer fellowship for basic science research, his BA in Economics from Washington University in St. Louis (2008-2012), where he graduated with College Honors and an MBA in Healthcare and Pharmaceutical & Entrepreneurship from Columbia Business School (2016-2018) where he graduated with Dean’s Honors and Distinction.
Positions
- Company NameKorsana Biosciences, Inc.Stock CodeKRSAPositionIndependent DirectorColleagues
- JVJonathan ViolinPresident, CEO, Secretary & Director
- TKTomas KiselakIndependent Chairman
- MJMark Joseph VignolaChief Financial Officer
- GWGan WeiChief Technical Officer
- MLMatthew LeoniChief Medical Officer
- KBKyle BreidenstineSenior Vice President of Finance & Treasurer
- MPMichelle PerniceIndependent Director
- HHHeidi HensonIndependent Director
